Evidence map›Paper›PMID 38999000›Full record

ArticleMolecules (Basel, Switzerland)2024

New 3-(Dibenzyloxyphosphoryl)isoxazolidine Conjugates of N1-Benzylated Quinazoline-2,4-diones as Potential Cytotoxic Agents against Cancer Cell Lines.

Magdalena Łysakowska, Iwona E Głowacka, Ewelina Honkisz-Orzechowska, Jadwiga Handzlik, Dorota G Piotrowska

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Study of Cytotoxicity of Pyrrolo[3,4-International journal of molecular sciences · 2026
    Article
  3. Article
  4. Article
  5. Phosphorylated Nitrones-Synthesis and Applications.Molecules (Basel, Switzerland) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Magdalena ŁysakowskaBioorganic Chemistry Laboratory, Faculty of Pharmacy, Medical University of Lodz, Muszynskiego 1, 90-151 Lodz, Poland.ORCID 0000-0003-4461-6467
Iwona E GłowackaBioorganic Chemistry Laboratory, Faculty of Pharmacy, Medical University of Lodz, Muszynskiego 1, 90-151 Lodz, Poland.ORCID 0000-0001-7567-5860
Ewelina Honkisz-OrzechowskaDepartment of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland.ORCID 0000-0002-2046-4879
Jadwiga HandzlikDepartment of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Krakow, Poland.ORCID 0000-0002-3674-3581
Dorota G PiotrowskaBioorganic Chemistry Laboratory, Faculty of Pharmacy, Medical University of Lodz, Muszynskiego 1, 90-151 Lodz, Poland.ORCID 0000-0003-3792-8796

Funding

Jagiellonian University N42/DBS/000331Jagiellonian University N42/DBS/000332Medical University of Lodz 503/3-014-01/503-31-001
6 · The paper itself

Abstract

In this study, a new series of

Indexed as

Antineoplastic AgentsCell ProliferationApoptosisCell Line, TumorCell SurvivalDrug Screening Assays, AntitumorHumansIsoxazolesMolecular StructurePC-3 CellsQuinazolinonesStructure-Activity RelationshipAntineoplastic AgentsIsoxazolesQuinazolinonesanticancer activityapoptosiscis/trans-isoxazolidinesphosphonatesquinazoline-2,4-dionessafety

Identifiers

PMID38999000
PMCPMC11243672

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.